Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy

The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to anti-PD-1 immunotherapy in metastatic melanoma after 2 cycles of ANTI-PD1. 20 patients will be enrolled and undergo three PET/CT scans: a baseline PET-CT, an early research PET-CT after 2 cycles of anti-PD1 (PET1) and a PET-CT at 3 months of initiation of treatment. Treatment response on FDG PET-CT will be assessed according to PERCIST criteria.

Trial Details

NCT ID
NCT03888950
Phase
NA
Sponsor
Centre Hospitalier Universitaire de Nice
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • FDG PET-CT
Locations (sample)
  • Nice, CHU de NICE, France|43.70313,7.26608

Key Eligibility Criteria

  • Age greater than or equal to 18 years,
  • Patient with advanced melanoma proved histologically, not BRAF mutated, BRAFV600 mutated and wild mutated, cutaneous or unknown primary melanoma ha…
  • Patient having social insurance,
  • Patient who has signed informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →